| P/E (FY) | 86.6 | Sales (TTM) | SEK 1.87B |
| Earnings (TTM) | SEK 428.4M | ROE | 17.91% |
| Net Margin | 22.94% | ROIC | 98.30% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 45.96% |
Camurus AB (publ) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases across Europe, Africa, the Middle East, North America, and Asia. Its marketed products include the buprenorphine injection Buvidal and Brixadi for opioid dependence and use disorder, and its pipeline spans candidates for chronic pain, acromegaly and neuroendocrine tumors, pulmonary arterial hypertension, genetic obesity disorders, prostate cancer, and other indications. The company works with partners such as Braeburn, Rhythm Pharmaceuticals, Gubra, and Eli Lilly, several drawing on its FluidCrystal technology. Camurus was founded in 1991 and is headquartered in Lund, Sweden.
| Market Cap | — | Trading Days | 2625 |
| 52W High | 754.50 |
| 52W Low | 430.80 |
| % Off High | −17.36% |
| YTD | 1.22% | 1Y | −12.24% |
| 3Y | 110.07% | 5Y | 249.50% |
| 10Y | 708.33% | Since incept. (ann.) | 24.50% |
| Ann. Volatility (1Y) | 48.66% | Ann. Volatility (3Y) | 48.63% |
| Sharpe (1Y) | −0.03 | Sharpe (3Y) | 0.78 |
| Max Drawdown (1Y) | −40.37% | Max Drawdown (3Y) | −40.37% |
| Beta (3Y, vs SPY) | 1.05 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.14T | 52.7 |
| JNJ | JOHNSON & JOHNSON | $639.90B | 24.1 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| AMGN | AMGEN INC | $209.21B | 27.2 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| GILD | GILEAD SCIENCES, INC. | $164.79B | 19.6 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| SYK | STRYKER CORP | $135.04B | 41.9 |
| BMY | BRISTOL MYERS SQUIBB CO | $128.85B | 18.2 |
| ISRG | INTUITIVE SURGICAL INC | $124.74B | 44.9 |
